Compare NOA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOA | AUTL |
|---|---|---|
| Founded | 1953 | 2014 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.6M | 388.6M |
| IPO Year | 2006 | 2025 |
| Metric | NOA | AUTL |
|---|---|---|
| Price | $13.49 | $1.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 67.3K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $14.77 | $80.32 |
| Revenue Next Year | $5.43 | $53.96 |
| P/E Ratio | $18.05 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $12.07 | $1.18 |
| 52 Week High | $17.68 | $2.70 |
| Indicator | NOA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 46.27 |
| Support Level | $13.26 | $1.41 |
| Resistance Level | $14.61 | $1.73 |
| Average True Range (ATR) | 0.40 | 0.12 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 30.70 | 29.54 |
North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment Canada, Heavy Equipment Australia, and Other. Heavy Equipment Canada and Heavy Equipment Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes mine management contract work in the United States, its external maintenance and rebuild programs.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.